

Supplementary Table 4. Results of the sensitivity analysis with variables including remdesivir therapy, vaccination status, and infection with Delta variant

Variable	Initial OR (95% CI)	<i>p</i> value	Peak OR (95% CI)	<i>p</i> value
Elevated initial KL-6 level	5.42 (1.84–15.92)	0.002	-	-
Elevated peak KL-6 level	-	-	5.42 (1.58–18.59)	0.01
Age	1.05 (1.01–1.10)	0.02	1.06 (1.01–1.10)	0.01
Cardiovascular diseases	1.59 (0.53–4.77)	0.41	1.97 (0.66–5.86)	0.22
Solid cancer	8.42 (2.33–30.41)	0.001	8.42 (2.39–29.67)	< 0.001
COVID-19 severity				
Asymptomatic to moderate				
Severe	0.81 (0.10–6.67)	0.85	0.74 (0.10–5.71)	0.77
Critical	2.80 (0.35–22.62)	0.34	2.17 (0.29–16.47)	0.45
Remdesivir therapy	1.73 (0.47–6.34)	0.41	1.53 (0.42–5.52)	0.52
COVID-19 vaccination	1.54 (0.47–5.06)	0.47	1.24 (0.39–3.97)	0.71
Delta variant	0.42 (0.15–1.22)	0.11	0.44 (0.15–1.28)	0.13
Elevated CRP (≥ 7.5 mg/dL)	3.14 (1.13–8.72)	0.03	3.26 (1.16–9.17)	0.03

OR, odds ratio; CI, confidence interval; KL-6, Krebs von den Lungen-6; CRP, C-reactive protein.